• 1. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 2. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 3. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330
• 4. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 5. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389

Recent Advances in the Study of 2-Pyridinemethanol, 4-bromo-3,5-dimethyl- (CAS: 220770-78-5) in Chemical Biology and Pharmaceutical Research

The compound 2-Pyridinemethanol, 4-bromo-3,5-dimethyl- (CAS: 220770-78-5) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This research brief aims to summarize the latest findings related to this compound, focusing on its synthesis, biological activity, and potential applications in drug development.

Recent studies have highlighted the role of 2-Pyridinemethanol, 4-bromo-3,5-dimethyl- as a versatile intermediate in the synthesis of novel bioactive molecules. Its bromo and dimethyl substituents make it a valuable building block for the development of targeted therapies, particularly in oncology and infectious diseases. Researchers have successfully utilized this compound in the synthesis of inhibitors targeting key enzymes involved in cancer cell proliferation and microbial pathogenesis.

One of the most promising applications of 2-Pyridinemethanol, 4-bromo-3,5-dimethyl- is in the development of kinase inhibitors. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its efficacy as a core structure in the design of selective kinase inhibitors, showing potent activity against several cancer-related kinases. The compound's ability to form stable interactions with the ATP-binding site of kinases makes it particularly valuable for structure-based drug design.

In addition to its therapeutic potential, recent research has explored the compound's physicochemical properties and structure-activity relationships (SAR). Advanced computational modeling techniques, including molecular dynamics simulations and quantum mechanical calculations, have provided insights into its conformational flexibility and electronic properties. These studies have contributed to a better understanding of how structural modifications can enhance its biological activity and pharmacokinetic profile.

The safety profile and toxicity of 2-Pyridinemethanol, 4-bromo-3,5-dimethyl- have also been investigated in recent preclinical studies. While initial results indicate a favorable safety margin at therapeutic doses, further research is needed to fully characterize its metabolic pathways and potential off-target effects. Current efforts are focused on optimizing its formulation to improve bioavailability and reduce potential side effects.

Looking forward, the unique properties of 2-Pyridinemethanol, 4-bromo-3,5-dimethyl- position it as a promising candidate for the development of next-generation therapeutics. Ongoing research is exploring its potential in combination therapies and as a platform for the development of targeted drug delivery systems. The compound's versatility and demonstrated biological activity suggest it will continue to be an important focus of chemical biology and pharmaceutical research in the coming years.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)